Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation

BACKGROUND: Hypercholesterolaemia is common in patients after cardiac transplantation. Monoclonal antibodies that inhibit proprotein convertase subtilisin-kexin type 9 (PCSK9) reduce low-density lipoprotein (LDL) cholesterol levels and subsequently the risk of cardiovascular events in patients with...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :PLoS One
Главные авторы: Kühl, Michael, Binner, Christian, Jozwiak, Joanna, Fischer, Julia, Hahn, Jochen, Addas, Alaeldin, Dinov, Boris, Garbade, Jens, Hindricks, Gerhard, Borger, Michael
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2019
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6335020/
https://ncbi.nlm.nih.gov/pubmed/30650126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0210373
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы